Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272787 | 0.86 | SMN1; SMN2 (0.39) | SMN1; SMN2FKBP1ALMNACYP3A4TSHR | |
| SCHEMBL3107583 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2FKBP1ALMNAPREPHTT | |
| SCHEMBL3274656 | 0.76 | SMN1; SMN2 (0.41) | SMN1; SMN2FKBP1ALMNAPREPHTT | |
| SCHEMBL3273428 | 0.75 | PDK1 (0.42) | SMN1; SMN2FKBP1ALMNAPREPHTT | |
| SCHEMBL3272148 | 0.75 | PREP (0.45) | SMN1; SMN2FKBP1ALMNAPREPHTT | |
| SCHEMBL19100157 | 0.74 | LMNA (0.46) | SMN1; SMN2LMNACYP3A4TSHRMAPT | |
| SCHEMBL7300040 | 0.73 | PREP (0.51) | FKBP1ACYP3A4TSHRPREPALDH1A1 | |
| SCHEMBL18334891 | 0.73 | TGM2 (0.46) | SMN1; SMN2FKBP1ALMNACYP3A4TSHR | |
| SCHEMBL3272958 | 0.72 | ABCB1 (0.46) | MAPTSYKHTTABCB1 | |
| SCHEMBL13382307 | 0.72 | ABCB1 (0.46) | MAPTSYKHTTABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | SMN1; SMN2 2301/4885FKBP1A 2817/4885LMNA 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.